Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Chicago Capital LLC

Chicago Capital LLC decreased its holdings in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 29.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 102,171 shares of the medical research company's stock after selling 42,395 shares during the quarter. Chicago Capital LLC's holdings in Edwards Lifesciences were worth $6,742,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Park Avenue Securities LLC grew its position in Edwards Lifesciences by 0.5% during the second quarter. Park Avenue Securities LLC now owns 23,484 shares of the medical research company's stock valued at $2,169,000 after acquiring an additional 108 shares during the period. City State Bank grew its holdings in shares of Edwards Lifesciences by 16.5% during the 2nd quarter. City State Bank now owns 917 shares of the medical research company's stock worth $85,000 after purchasing an additional 130 shares during the period. Chapin Davis Inc. increased its position in Edwards Lifesciences by 1.7% during the 1st quarter. Chapin Davis Inc. now owns 8,548 shares of the medical research company's stock worth $817,000 after purchasing an additional 140 shares in the last quarter. Valley National Advisers Inc. raised its holdings in Edwards Lifesciences by 6.0% in the first quarter. Valley National Advisers Inc. now owns 2,677 shares of the medical research company's stock valued at $255,000 after buying an additional 152 shares during the period. Finally, Choreo LLC lifted its position in Edwards Lifesciences by 4.1% during the first quarter. Choreo LLC now owns 3,840 shares of the medical research company's stock valued at $367,000 after buying an additional 153 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

Edwards Lifesciences Stock Up 2.6 %

Edwards Lifesciences stock traded up $1.80 during midday trading on Friday, hitting $70.27. The stock had a trading volume of 5,424,803 shares, compared to its average volume of 4,573,039. The business has a fifty day moving average price of $67.81 and a 200 day moving average price of $79.08. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The stock has a market cap of $42.34 billion, a P/E ratio of 30.29, a P/E/G ratio of 2.83 and a beta of 1.13. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The business had revenue of $1.63 billion during the quarter, compared to the consensus estimate of $1.65 billion. During the same period in the previous year, the business earned $0.66 EPS. The business's quarterly revenue was up 6.7% on a year-over-year basis. Research analysts predict that Edwards Lifesciences Co. will post 2.71 EPS for the current year.

Insiders Place Their Bets

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total value of $330,400.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares of the company's stock, valued at approximately $3,101,530.88. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of the stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the sale, the vice president now directly owns 29,333 shares of the company's stock, valued at $2,051,843.35. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business's stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total transaction of $330,400.00. Following the transaction, the vice president now directly owns 46,936 shares of the company's stock, valued at approximately $3,101,530.88. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 16,250 shares of company stock valued at $1,099,238. Company insiders own 1.29% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on EW. Truist Financial dropped their price objective on shares of Edwards Lifesciences from $82.00 to $71.00 and set a "hold" rating for the company in a research report on Friday, September 13th. Wells Fargo & Company cut their price objective on Edwards Lifesciences from $90.00 to $80.00 and set an "overweight" rating on the stock in a research report on Monday, September 9th. Barclays decreased their target price on Edwards Lifesciences from $90.00 to $80.00 and set an "overweight" rating for the company in a research report on Monday, September 9th. JPMorgan Chase & Co. lowered Edwards Lifesciences from an "overweight" rating to a "neutral" rating and lowered their target price for the company from $105.00 to $72.00 in a research note on Thursday, July 25th. Finally, The Goldman Sachs Group reduced their price target on Edwards Lifesciences from $107.00 to $91.00 and set a "buy" rating on the stock in a research report on Friday, July 26th. Fifteen analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Edwards Lifesciences presently has a consensus rating of "Hold" and an average target price of $75.81.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.